Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of KR23248 in Healthy Adult Subjects
NCT07585383Phase 1Not yet recruiting
- Sponsor
- Jiangxi Kvvit Pharmaceutical
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of KR23248 in schizophrenia (9 arms), sponsored by Jiangxi Kvvit Pharmaceutical. Primary endpoint: Incidence of adverse events. Planned start May 2026; status: not yet recruiting.
02
Drugs
KR23248
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07585383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585383.